Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. (symbol: LGVN) is a clinical-stage biotechnology company at the forefront of regenerative medicine. The company is dedicated to developing innovative cellular therapeutics to address unmet medical needs related to aging and life-threatening conditions. Longeveron's lead investigational product, Lomecel-B™, is an advanced stem cell formulation derived from the bone marrow of young, healthy adult donors. This allogeneic (‘off-the-shelf’) product is currently being investigated for its potential to promote tissue repair and healing.
Lomecel-B™ is being explored for three primary indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's Disease (AD), and Aging-related Frailty. The unique mechanisms of action of Lomecel-B™, which include stimulating new blood vessel formation, modulating the immune system, reducing tissue fibrosis, and promoting the division of endogenous cells, make it a promising candidate for these conditions.
In its HLHS program, Longeveron has seen remarkable results. A Phase 1 trial showcased a 100% transplant-free survival rate at up to five years of age, a significant milestone considering the fatality and transplant rates historically associated with this rare pediatric disease. The ongoing Phase 2 trial aims to compare outcomes of standard care plus Lomecel-B™ vs. standard care alone, with an eye towards accelerated or final approval from the FDA based on these promising results.
For Alzheimer’s Disease, Longeveron has completed a Phase 2a CLEAR-MIND trial involving 49 patients, building on the success of its initial Phase 1 trial. Encouraging efficacy signals from this study are driving the company to seek partnerships and funding to advance this program further, addressing a vast unmet need with potential significant market opportunities.
On the financial front, Longeveron is actively managing expenses and seeking additional capital, crucial for continuing its operations and funding its ambitious pipeline. The company has undertaken measures such as a reverse stock split and filing a registration statement with the SEC to facilitate capital raising. The company’s cash resources are currently insufficient to fund operations beyond the second quarter of 2024, highlighting the urgency of securing additional financing.
CEO Wa’el Hashad, marking his first anniversary with the company, emphasizes a strategic roadmap focused on leveraging Longeveron's scientific strengths while navigating the capital market environment. The company is also exploring revenue-generating activities like contract development and manufacturing services (CDMO) to bolster its financial position.
Longeveron's commitment to responsible financial stewardship and strategic operational goals positions it as a significant player in the regenerative medicine field. The company remains dedicated to bringing Lomecel-B™ to market, potentially transforming the treatment landscape for patients suffering from devastating conditions.
Longeveron Inc. (NASDAQ: LGVN) announced that its Co-founder and Chairman, Dr. Joshua M. Hare, will be a panelist at the National Academy of Medicine’s workshop on June 15, 2021. The symposium, titled “Transformative Advances in Biological Sciences for Healthy Longevity,” aims to develop a Global Roadmap for Healthy Longevity. Longeveron is focused on cell-based therapies for aging-related diseases, with ongoing clinical trials for its lead product, Lomecel-B, targeting aging frailty and Alzheimer’s disease. Top-line data from recent trials is expected in Q3 2021.
Longeveron (NASDAQ: LGVN) announced the appointment of Ursula Ungaro to its Board of Directors, effective June 1, 2021. Ungaro, who has served on the U.S. District Court for the Southern District of Florida since 1992, brings extensive legal experience, particularly in civil and securities law. Her retirement from the judiciary was motivated by her desire to contribute to Longeveron's growth in cellular therapies, including the development of Lomecel-B for aging-related conditions. CEO Geoff Green expressed confidence in her ability to guide the company's clinical advancements and commercialization efforts.
Longeveron Inc. (NASDAQ: LGVN) has appointed Dan Gincel, Ph.D., as Senior Vice President of Strategic Collaborations & Scientific Affairs. Gincel brings over 20 years of experience in regenerative medicine, including leadership roles in public-private partnerships. Previously, he managed over $150 million in funding while at the Maryland Stem Cell Research Fund. CEO Geoff Green noted Gincel's expertise will help advance Longeveron's mission to develop cell therapies for aging-related diseases. The company is currently conducting Phase 1 and 2 clinical trials for multiple conditions.
Longeveron Inc. (NASDAQ: LGVN) provided a business update and Q1 financial results as of March 31, 2021. The company is developing allogeneic cell therapies targeting chronic aging-related diseases, including Alzheimer's. Notably, the Phase 1 Alzheimer’s study showed Lomecel-B to be well tolerated with no serious adverse events and evidence of slowing cognitive decline. Longeveron plans to initiate a Phase 2 study in the second half of the year and expects to announce top-line results from Phase 2 Aging Frailty trials in Q3. The upcoming presentations at significant conferences highlight the company's ongoing research.
Longeveron Inc. (NASDAQ: LGVN) announced it will release its first quarter 2021 financial results on May 14, 2021, before US market open. Management will host a conference call at 8:30 AM that day. The company focuses on cellular therapies for aging-related and life-threatening conditions, with its lead product, LOMECEL-B™, undergoing Phase 1 and 2 clinical trials for various serious conditions, including Aging Frailty and Alzheimer's disease. The aim is to advance therapies into pivotal Phase 3 trials for regulatory approval and commercialization.
Longeveron announced positive Phase 1 study results of Lomecel-B for treating Alzheimer's disease and completed two Phase 2 trials evaluating its safety and efficacy in Aging Frailty subjects. Top-line results from these studies are expected in Q3 2021. The CEO, Geoff Green, will present at the Benzinga Global Small Cap Conference on May 13-14, 2021, highlighting the company's clinical research efforts, including aging-related conditions. Longeveron aims to advance Lomecel-B towards regulatory approval and commercialization.
Longeveron Inc. (NASDAQ: LGVN) has been selected to present at the 2021 World Stem Cell Summit from June 14-18. Dr. Joshua Hare, Chief Science Officer, will discuss the Longevity Agenda and present findings on Lomecel-B, a therapy targeting aging-related conditions like Alzheimer's and Aging Frailty. The company anticipates sharing results from clinical trials in the third quarter. Geoff Green, CEO, expressed pride in participating in this prestigious event, emphasizing the promise of cell-based therapies in improving healthspan.
Longeveron has completed a Phase I/II clinical study evaluating Lomecel-B's effectiveness in enhancing immune response to the flu vaccine in elderly individuals with aging frailty. Funded partially by the Maryland Technology Development Corporation and the National Institute on Aging, the study involved randomized, double-blinded trials at seven centers in Florida and Maryland. Results are expected in Q3 2021, revealing Lomecel-B's potential to mitigate inflammation and improve B cell function for better vaccine response in this vulnerable population.
Longeveron Inc. (NASDAQ: LGVN) announced positive final results from its Phase 1 clinical trial of Lomecel-B for treating mild Alzheimer’s disease. The study met its primary safety endpoint and showed that cognitive decline was slower in patients receiving low-dose Lomecel-B compared to placebo. Notably, quality of life metrics improved, with significant differences at 26 weeks. Complete trial results will be published soon. The company is poised to initiate a Phase 2 study in the latter half of 2021, indicating a proactive approach towards potential Alzheimer's treatments.
Longeveron Inc. (NASDAQ: LGVN) reported its financial results for Q4 and full year 2020, highlighting a net loss of $1.4 million for Q4 compared to $0.5 million in Q4 2019. Revenue was $1.2 million in Q4 2020, down from $1.8 million in Q4 2019, primarily due to decreased grant revenue. However, revenue from the Bahamas Registry Trial increased by 119% year-over-year. The company secured a $29.1 million IPO and anticipates sufficient cash to support operations through Q4 2022. Upcoming results from multiple clinical trials are expected in 2021.
FAQ
What is the current stock price of Longeveron (LGVN)?
What is the market cap of Longeveron (LGVN)?
What is Longeveron Inc.?
What is Lomecel-B™?
What conditions is Lomecel-B™ being investigated for?
How has Longeveron performed in its HLHS trials?
What are the financial challenges Longeveron faces?
What are the future plans for Longeveron's Alzheimer's Disease program?
How is Longeveron managing its financial position?
Who is the CEO of Longeveron?
What are Longeveron's core business objectives?
Where can I find more information about Longeveron?
